The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 56, Issue 66, 2001, Pages 22-29

  Warner, John O ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Asthma; Children; Cysteinyl leukotriene; Eosinophils; Leukotriene receptor antagonists; Montelukast

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO; PRANLUKAST; ZAFIRLUKAST;

ASTHMA; BRONCHOSPASM; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; EOSINOPHILIA; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SPUTUM EXAMINATION; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD WELFARE; CHRONIC DISEASE; HUMANS; LEUKOTRIENE ANTAGONISTS;

EID: 0034973550     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Global initiative for asthma: Global strategy for asthma management and prevention
2. Changes in asthma prevalence: Two surveys 15 years apart
3. Changing patterns of asthma hospitalization among children: 1979 to 1987
4. Review of prescribed treatment for children with asthma in 1990
5. Childhood asthma and lung function in mid-adult life
6. Prognosis of asthma from childhood to adulthood
7. Third International Pediatric Consensus Statement on the management of childhood asthma
8. The British guidelines on asthma management: 1995 Review and position statement
9. Asthma and inflammation
10. Bronchoalveolar lavage findings suggest two different forms of childhood asthma
11. Bronchoalveolar cell profiles in children with asthma, infantile wheeze, chronic cough, or cystic fibrosis
12. Noncompliance and treatment failure in children with asthma
13. Drug utilization and quality of life in patients with airways limitations using inhaled steroids on a PRN basis
14. Comparison of patients' compliance with prescribed oral and inhaled medications
15. The complexity of treatment adherence in adults with asthma: Challenges and opportunities
16. Patient and regimen-related factors that influence compliance with asthma therapy
17. The effect of prescribed daily dose frequency on patient medication compliance
18. Compliance in asthma
19. A comparison of the efficacy and safety of inhaled corticosteroids in asthma
20. Efficacy and safety of inhaled corticosteroids: New developments
21. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate
22. Endocrine and lung function in asthmatic children on inhaled corticosteroids
23. Inhaled corticosteroid use and bone mineral density in patients with asthma
24. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
25. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
26. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma
27. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment
28. Treatment of asthma with drugs modifying the leukotriene pathway
29. Antileukotriene drugs in the management of asthma
30. 4 receptor antagonist, in subjects with bronchial asthma
31. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial
32. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses
33. Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma
34. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy
35. Comparison of the effects of oral montelukast versus inhaled beclomethasone therapy on asthma control
36. Montelukast added to inhaled beclomethasone in treatment of asthma
37. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
38. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid
39. Effect of oral prednisone on airway inflammatory mediators in atopic asthma
40. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Modulation by dexamethasone
41. 4 excretion
42. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: Pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects
43. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
44. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids
45. Evaluation of the safety profile of montelukast (MK-0476) in adult and pediatric patients (aged 6 to 14 years)
46. Montelukast
47. Montelukast for chronic asthma in 6- to 14-year old children. A randomized, double-blind trial
48. Evaluation of the long-term effect of montelukast in adult (≥ 15 years) and pediatric (6- to 14-years) patients
49. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma
50. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
51. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial
52. Montelukast reduces airway inflammation in asthma: A randomized, controlled trial
53. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma
54. Bronchial biopsy specimen variability: Requirement for large sample size and repeated measurements to improve reliability
55. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma
56. Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists
57. Leukotriene modifiers and Churg-Strauss syndrome: Adverse effect or response to corticosteroid withdrawal?